AMAnnye Vitória Moraes

Annye Vitória Moraes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annye Vitória Moraes has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardioprotective Effect of Nanoencapsulated α-Amyrin in Spontaneously Hypertensive Rats with Metabolic Syndrome

    by Gabriela Pereira da Silva, Luana Ale Bertoncello Pael, Maria Luiza Fidelis da Silva, Maria Medina de Azevedo, Telma Lélia Gonçalves Schultz de Carvalho, Annye Vitória Moraes, Harveli Darpy Balouta, Leticia de Andrade Maldonado Aires, Tatiane Pereira de Souza, Serafim Florentino Neto, et al.

    Background/Objectives: Metabolic syndrome (MS) encompasses a cluster of disorders that significantly increase cardiovascular risk. While α-amyrin exhibits antioxidant and anti-inflammatory properties, its poor aqueous solubility and low oral bioavailability hinder its clinical use. This study evaluated the cardioprotective effects of α-amyrin-loaded polymeric nanocapsules (NCαA) in spontaneously hypertensive rats (SHR) with sucrose-induced MS. Methods: First, NCαA was prepared via interfacial deposition of a preformed polymer following organic solvent displacement. The formulation was characterized for particle size, zeta potential, morphology, encapsulation efficiency, and storage stability. Spontaneously hypertensive rats (SHR) received 20% sucrose for 8 weeks and were treated daily by oral gavage for 28 days with NCαA (0.1, 0.3, or 1 mg/kg), unformulated α-amyrin (1 mg/kg), hydrochlorothiazide (25 mg/kg), vehicle, or blank nanocapsules. Cardiovascular, electrocardiographic, echocardiographic, vascular, renal, and biochemical parameters were subsequently assessed. Results: Polymeric NCαA showed spherical and uniform morphology (195.10 ± 1.55 nm; PDI: 0.144; zeta potential: −52.60 mV), 85.85% encapsulation efficiency, efficient sustained release, and 90-day shelf-life stability. In vivo, MS control rats exhibited significant weight gain, hypertension, increased S-wave negative deflection depth, reduced ejection fraction, impaired acetylcholine-mediated vasodilation, depressed serum nitrite, and elevated malondialdehyde. Treatment with NCαA (particularly at 0.3 and 1 mg/kg), unlike unformulated α-amyrin, prevented excessive weight gain, normalized blood pressure, reversed electrophysiological/echocardiographic markers of cardiac overload, restored nitric oxide bioavailability, attenuated lipid peroxidation, and maintained renal hydroelectrolytic balance. Conclusions: Polymeric nanoencapsulation yielded stable nanocapsules with high sustained release, overcoming the biopharmaceutical limitations of α-amyrin. NCαA provides comprehensive cardioprotection against MS-induced damage, representing a promising multi-target strategy for cardiometabolic disorders.

  • Open Access

    Green-Synthesized Gold Nanoparticles Using Pfaffia glomerata Extract Improve Maternal Hypertension and Angiogenic Markers in Pregnant Hypertensive Rats

    by Maria Medina de Azevedo, Maria Luiza Fidelis da Silva, Gabriela Pereira da Silva, Joyner David Anaya Miranda, Annye Vitória Moraes, Luana Ale Bertoncello Pael, Telma Lélia Gonçalves Schultz de Carvalho, Giselle Nathaly Calaça, Thainá Aparecida Rafael Silva, Bianca Viana Silva, et al.

    Background: Hypertensive disorders of pregnancy present a major global health challenge. Green nanotechnology offers a strategy to enhance the stability and efficacy of bioactive natural products. This study evaluated gold nanoparticles green-synthesized with Pfaffia glomerata extract (AuNPs-PG) against gestational hypertension and fetal complications in spontaneously hypertensive rats (SHRs). Methods: P. glomerata root extract was characterized by UHPLC-MS/MS. AuNPs-PG were green-synthesized with 2 mmol/L HAuCl4 (1:5 v/v) at 40 °C and characterized by UV-Vis and DLS. Pregnant Wistar-Kyoto and SHRs were divided into naive, negative control (NC), amlodipine (5 mg/kg), and AuNPs-PG groups (0.03, 0.1, and 0.3 mg/kg) treated daily on gestational days 1–18 to evaluate maternal cardiovascular, renal, biochemical, and reproductive outcomes. Results: UHPLC-MS/MS identified 38 compounds. AuNPs-PG showed a plasmon band at 520–550 nm and 88.1 nm hydrodynamic diameter. In SHRs, 0.3 mg/kg AuNPs-PG reduced systolic blood pressure by 18.5% and mean arterial pressure by 15.4%, while mitigating vascular dysfunction by lowering phenylephrine vasoconstriction by 52.7% and boosting acetylcholine vasodilation by 239.3%. Treatment shortened QTc interval by 26.4%, normalized T-wave inversion, and restored renal excretion, increasing urinary volume by 75.0% and sodium by 94.2%. Furthermore, AuNPs-PG elevated placental growth factor by 180.9%, lowered malondialdehyde by 63.5%, and preserved placental histology. Consequently, mean fetal weight increased by 21.6%, implantation index by 50.5%, and offspring-to-mother ratio by 129.6%. Conclusions: AuNPs-PG (0.3 mg/kg) effectively mitigate maternal and fetal complications in gestational hypertension. Gold nanoparticles serve as nanocarriers, whereas surface-adsorbed phytochemicals drive the biological effects.

  • Open Access

    Ostrich oil (Struthio camelus) traditional knowledge, applications, and future perspectives

    by Jesus Rafael Rodriguez Amado, Annye Vitória Moraes, Andréa Roledo Lima, Arquimedes Gasparotto Junior, Marco António Utrera Martines, Ariadna Lafourcade Prada

    Ostrich (Struthio camelus) oil emerges as a valuable source of bioactives with applications in nutraceutical, pharmaceutical, and cosmetic sciences. Despite its unique chemical composition rich in omega fatty acids and fat-soluble vitamins, research on its biological and commercial applications remains still limited. This review explores extraction methods, physicochemical properties, bioactive components, and the utility of this product in cosmetics, functional foods, and pharmaceuticals. It was made a deep review of scientific (Scopes, Dove, Elsevier) and patent sources (USPTO, WIPO, EPO) to explore ostrich oil extraction methods, composition, and uses. The quality of ostrich oils varies depending on the extraction method, diet, and environment. Supercritical fluid extraction produces oil with high purity but a limited yielding, while Low-Temperature rendering balances yield and oxidative stability. The oil has been shown to have antibacterial, wound healing, anti-inflammatory, and antioxidant properties, supporting its use in skincare, and osteoarthritic diseases. Minor bioactive components present in ostrich oil, including tocopherols, sterols, and vitamins A and E enhance their functional profile, making it an ideal candidate for dietary supplements, cosmetics, and pharmaceuticals. Additionally, its high thermal stability supports food applications, such as frying and goods products, where it improves sensory attributes and lipid profiles. Regulatory frameworks vary internationally, with stricter safety assessments in the US and EU compared to emerging markets. Despite its multifaceted benefits, research on ostrich oil remains still limited, necessitating more studies on dietary supplementation, extraction enhancements, and pharmaceutical applications. Optimizing farming practices, refining extraction techniques, and conducting clinical trials will be essential in establishing ostrich oil as a functional ingredient for cosmetics, food, and pharmaceutical applications.